Asian Stocks That Might Be Undervalued In February 2026
4 Mins Read
As global markets navigate a period of volatility, with concerns surrounding artificial intelligence and geopolitical tensions impacting investor sentiment, the Asian stock market presents intriguing opportunities for those seeking value. In this context, identifying stocks that may be undervalued requires a focus on companies with strong fundamentals and resilience to market fluctuations.
Here’s a peek at a few of the choices from the screener.
Overview: FIT Hon Teng Limited manufactures and sells mobile and wireless devices and connectors in Taiwan and internationally, with a market cap of HK$39.30 billion.
Operations: The company’s revenue is derived from Consumer Products, generating $671.57 million, and Intermediate Products, contributing $4.13 billion.
Estimated Discount To Fair Value: 49.6%
FIT Hon Teng is trading at HK$5.54, significantly below its estimated future cash flow value of HK$11, suggesting it is undervalued based on cash flows. Analysts anticipate a 36.7% annual earnings growth rate, surpassing the Hong Kong market’s average of 12.3%. Despite high share price volatility and low future return on equity forecast (11.6%), the company benefits from a framework sales agreement with Hon Hai Precision Industry Co., potentially enhancing revenue growth prospects.
SEHK:6088 Discounted Cash Flow as at Feb 2026
Overview: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative drugs in oncology and immunology both in China and internationally, with a market cap of approximately HK$101.95 billion.
Operations: The company’s revenue primarily comes from its pharmaceuticals segment, generating approximately CN¥1.50 billion.
Estimated Discount To Fair Value: 49.3%
Sichuan Kelun-Biotech Biopharmaceutical is trading at HK$437.2, substantially below its estimated future cash flow value of HK$862.98, indicating potential undervaluation based on cash flows. The company forecasts a robust annual revenue growth of 32.2%, outpacing the Hong Kong market’s average growth rate and expects profitability within three years. Recent regulatory approvals for sacituzumab tirumotecan in China could bolster revenue streams, though high volatility remains a consideration for investors.
SEHK:6990 Discounted Cash Flow as at Feb 2026
Overview: Nan Juen International Co., Ltd. operates in the research, development, manufacturing, and trading of steel ball guide rails across global markets including the United States, Asia, Europe, and Africa with a market cap of NT$27.20 billion.
Operations: The company generates revenue of NT$2.25 billion from the manufacture and sale of steel ball rails.
Estimated Discount To Fair Value: 47.4%
Nan Juen International’s recent earnings report showed a significant increase in net income, with TWD 130.27 million for Q3 compared to TWD 43.51 million last year, reflecting strong operational performance. The stock trades at NT$407.5, well below its future cash flow value of NT$775.26, suggesting it is undervalued based on cash flows. Despite high share price volatility recently, projected earnings and revenue growth remain robust at 67.2% and 29.4% annually over the next three years respectively.
TPEX:6584 Discounted Cash Flow as at Feb 2026
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:6088 SEHK:6990 and TPEX:6584.
This article was originally published by Simply Wall St.
